LXRX Live signals | Maximize Profits with Getagraph.com

BUY 98969 min ago

@ $3.29

Issued: 14 Feb 2024 @ 13:44

Return: -48.02%

Previous signal: Feb 14 - 09:31

Previous signal: Sell

Return: 4.44 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	3.96M
Average Volume	4.89M
Market Cap	421.07M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.200 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.14
ATR14	$0.00400 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	Artal International S.c.a.	Buy	1 150 922	Series A Convertible Preferred Stock
2024-02-28	Alexander Kristen	Buy	15 927	Common Stock
2024-02-28	Alexander Kristen	Sell	11 793	Common Stock
2024-02-28	Alexander Kristen	Buy	10 616	Common Stock
2024-02-28	Alexander Kristen	Buy	2 700	Common Stock

INSIDER POWER
92.60
Last 98 transactions
Buy: 35 947 123 \| Sell: 970 903

Volume Correlation

Long: -0.03 (neutral)

Short: 0.31 (neutral)

Signal:(70.17) Neutral

Lexicon Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lexicon Pharmaceuticals Correlation - Currency/Commodity

-0.18
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

Lexicon Pharmaceuticals Financials

Annual	2023
Revenue:	$1.20M
Gross Profit:	$565 000 (46.93 %)
EPS:	$-0.800

Q4	2023
Revenue:	$702 000
Gross Profit:	$485 000 (69.09 %)
EPS:	$-0.200

Q3	2023
Revenue:	$162 000
Gross Profit:	$155 000 (95.68 %)
EPS:	$-0.210

Q2	2023
Revenue:	$317 000
Gross Profit:	$309 000 (97.48 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.